The toxicology studies reported here were conducted to obtain FDA approval for the phase I/II clinical trials for the oral delivery of ACE2/Ang(1–7) to treat COVID-19 patients, or for the topical delivery of ACE2 gum to decrease the infection and transmission of SARS-CoV-2 (NCT05433181). Here, ACE2 is linked to COVID-19.